Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308165 · ClinicalTrials.gov registry record · Phase 1
Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
A Phase 1 study of Brain Neoplasms, Primary Malignant, sponsored by Jeffrey N. Bruce.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00308165 is a Phase 1 study of Brain Neoplasms, Primary Malignant that has completed, run by Jeffrey N. Bruce. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00308165, a Phase 1 study of Brain Neoplasms, Primary Malignant, has completed, sponsored by Jeffrey N. Bruce.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and efficacy of a chemotherapeutic drug (topotecan) as it is given directly into brain tumors by a delivery technique called convection-enhanced delivery. This drug has been used for different types of cancer, but in this study it will be given by an experimental delivery technique designed to maximize the amount of drug delivered to the brain tumor and minimize the side effects in other parts of the body. This study will also evaluate advanced magnetic resonance (MR) imaging techniques. The study will assess quality of life parameters throughout the follow-up period.
Conditions Studied
Interventions
- DRUG Topotecan
- PROCEDURE Convection-Enhanced Delivery
Study Locations (1)
New York
- Columbia University Medical Center Neurological Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00308165
The ClinicalTrials.gov registry entry for NCT00308165 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeffrey N. Bruce, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Neoplasms, Primary Malignant appearing as the primary indexed condition, and to 2 interventions - of which Topotecan is the first listed.
NCT00308165 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00308165 about?
NCT00308165 is a clinical study titled "Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors". This study will evaluate the safety and efficacy of a chemotherapeutic drug (topotecan) as it is given directly into brain tumors by a delivery technique called convection-enhanced delivery. This drug has been used for different types of cancer, but in this study it will be given by an experimental ...
What is the current status of trial NCT00308165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2004-03. Estimated completion is 2016-01.
What conditions does trial NCT00308165 study?
This clinical trial studies the following conditions: Brain Neoplasms, Primary Malignant.
What interventions are being tested in trial NCT00308165?
The interventions under investigation include: Topotecan (DRUG), Convection-Enhanced Delivery (PROCEDURE).
Who is sponsoring clinical trial NCT00308165?
This trial is sponsored by Jeffrey N. Bruce, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00308165 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.